Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Common Equity of $52.7 million for Q1 2026, down 32.14% year-over-year from $77.7 million in Q1 2025, and up 21.57% quarter-over-quarter from $43.3 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $52.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 32.14% year-over-year to $52.7 million; the TTM figure through Mar 2026 stood at $52.7 million (down 32.14% YoY), while the FY2025 annual figure was $43.3 million, down 43.72% from the prior year.
- Common Equity for Q1 2026 stood at $52.7 million, up from $43.3 million in the prior quarter.
- The five-year high for Common Equity was $85.2 million in Q1 2022, with the low at $20.8 million in Q3 2025.
- The 5-year median for Common Equity is $69.0 million (2023), against an average of $65.1 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity increased 24.17% in 2024, then tumbled 67.9% in 2025.
- Lineage Cell Therapeutics' Common Equity stood at $71.9 million in 2022, then fell by 13.78% to $62.0 million in 2023, then climbed by 24.17% to $77.0 million in 2024, then tumbled by 43.72% to $43.3 million in 2025, then rose by 21.57% to $52.7 million in 2026.
- Business Quant data shows LCTX's Common Equity at $52.7 million in Q1 2026, $43.3 million in Q4 2025, and $20.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 60.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.92 Mn |
| Mar 31, 2026 | 52.70 Mn |
| Dec 31, 2025 | 43.35 Mn |
| Sep 30, 2025 | 20.80 Mn |
| Jun 30, 2025 | 47.11 Mn |
| Mar 31, 2025 | 77.66 Mn |
| Dec 31, 2024 | 77.01 Mn |
| Sep 30, 2024 | 64.79 Mn |
| Jun 30, 2024 | 66.88 Mn |
| Mar 31, 2024 | 70.99 Mn |
| Dec 31, 2023 | 62.02 Mn |
| Sep 30, 2023 | 66.66 Mn |
| Jun 30, 2023 | 71.26 Mn |
| Mar 31, 2023 | 69.02 Mn |
| Dec 31, 2022 | 71.94 Mn |
| Sep 30, 2022 | 77.55 Mn |
| Jun 30, 2022 | 81.50 Mn |
| Mar 31, 2022 | 85.22 Mn |
| Dec 31, 2021 | 90.90 Mn |
| Sep 30, 2021 | 119.59 Mn |